We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

17 hedge funds and large institutions have $964K invested in NeuroSense Therapeutics in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

433% more capital invested

Capital invested by funds: $181K → $964K (+$784K)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

55% more funds holding

Funds holding: 11 → 17 (+6)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

1.29% more ownership

Funds ownership: 0.84% → 2.13% (+1.3%)

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
3
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$216K
2
Squarepoint
Squarepoint
New York
+$72.3K
3
Morgan Stanley
Morgan Stanley
New York
+$42.6K
4
Jane Street
Jane Street
New York
+$41.6K
5
HF
HRT Financial
New York
+$31.4K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$31K
2
TSS
Two Sigma Securities
New York
-$13.7K
3
WAM
Warberg Asset Management
Illinois
-$9.95K
4
HC
Hurley Capital
New York
-$3.16K
5
UBS Group
UBS Group
Switzerland
-$962
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$282K +$216K +149,243 New
Morgan Stanley
2
Morgan Stanley
New York
$151K +$42.6K +29,399 +58%
YAG
3
Yorkville Advisors Global
New Jersey
$113K +$86.9K +60,000 New
Squarepoint
4
Squarepoint
New York
$94.4K +$72.3K +49,925 New
MIH
5
Meitav Investment House
Israel
$75.6K – – –
Jane Street
6
Jane Street
New York
$54.2K +$41.6K +28,689 New
HF
7
HRT Financial
New York
$41K +$31.4K +21,694 New
Commonwealth Equity Services
8
Commonwealth Equity Services
Massachusetts
$40K +$5.55K +3,830 +22%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$30K – – –
Marshall Wace
10
Marshall Wace
United Kingdom
$22.4K +$17.1K +11,828 New
Jones Financial Companies
11
Jones Financial Companies
Missouri
$20.7K +$15.8K +10,919 New
BNP Paribas Financial Markets
12
BNP Paribas Financial Markets
France
$12.9K +$9.85K +6,800 New
HC
13
Hurley Capital
New York
$12.3K -$3.16K -2,180 -25%
SS
14
SBI Securities
Japan
$8.42K +$6.2K +4,280 +2,446%
UBS Group
15
UBS Group
Switzerland
$3.04K -$962 -664 -29%
Carson Wealth (CWM LLC)
16
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
TIM
17
Total Investment Management
Arizona
$945 +$725 +500 New
XT
18
XTX Topco
Cayman Islands
– -$31K -33,706 Closed
TSS
19
Two Sigma Securities
New York
– -$13.7K -14,705 Closed
WAM
20
Warberg Asset Management
Illinois
– -$9.95K -10,700 Closed

NRSN Hedge Fund Activity: Q2 2025 in Review

17 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q2 2025, worth a combined $964K — up 433% from $181K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NRSN positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $216K. The largest seller was XTX Topco, exiting entirely with an estimated $31K sold.

  • 17 institutional investors held NeuroSense Therapeutics (NRSN) as of Q2 2025, up from 11 in Q1 2025.
  • Funds reported $964K of NeuroSense Therapeutics stock for Q2 2025, up 433% quarter-over-quarter.
  • 9 funds opened new NeuroSense Therapeutics positions in Q2 2025 and 3 closed out, a net change of +6 holders.
  • The largest NeuroSense Therapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $216K added.
  • The largest NeuroSense Therapeutics seller in Q2 2025 was XTX Topco, an estimated $31K sold.

Based on aggregated 13F filings for Q2 2025.